Navigation Links
Frost & Sullivan Determines a Real and Urgent Need for Novel Cancer Diagnostics Tests
Date:2/6/2013

ile these are positive signs, consolidation has increased the bargaining power of laboratories, allowing them to squeeze the prices of cancer-related tests. The demand is now for high-capacity, high-volume laboratory solutions, rather than high-value, labour-intensive tests like NAT.

"On the one hand, efforts will have to be made to facilitate the integration of novel NAT technologies with existing laboratory systems," advises Divyaa Ravishankar. "On the other hand, the development of innovative and more accurate tests, paralleled by initiatives at improving patient awareness about these new options, could create a 'pull' effect from patients, which could negate the increasing bargaining power of the centralised lab."

If you are interested in more information on this study, please send an email with your contact details to Anna Zanchi , Corporate Communications, at anna.zanchi@frost.com.

Western European In Vitro Cancer Diagnostics Market is part of the Life Sciences Growth Partnership Service programme, which also includes research in the following areas: Western European Genetic Testing and Screening Services Market and Western European In Vitro Diagnostics Market. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

    <
    '/>"/>

SOURCE Frost & Sullivan
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Best Practices Involving Product Innovation and Creation of Value Vital for Customer Retention, Finds Frost & Sullivan
2. Contract Research Organisations offer Promise of Innovative, Safe and Effective Drug Development, Says Frost & Sullivan
3. Medical Devices 2013: A Frost & Sullivan Executive MindXchange- Sustaining the Vitality of the Industry and Your Company
4. Proposed Regulatory Uniformity to Boost Venture Capital Investments in Healthcare Arena, Says Frost & Sullivan
5. Americas Interest in Obesity Surgery Soars Following its Success in Europe and ROW, Finds Frost & Sullivan
6. Advances in Cosmesis Increase Amputee Acceptance of Prosthesis and Orthotics Devices, Finds Frost & Sullivan
7. Increasing Prevalence of Heart Disease Drives Growth of Cardiac Biomarkers Diagnostics Market, Says Frost & Sullivan
8. Frost & Sullivan: Appropriate Channel Partners Vital in the Highly Fragmented Medical Devices Distribution Market in VITSK
9. Frost & Sullivan: TNF Inhibitors Lay the Groundwork for the Next Generation of Disease-Modifying Anti-Rheumatic Drugs
10. Private Healthcare Facilities Strengthen Cardiac Patient Monitoring Devices Market in CEE, Finds Frost & Sullivan
11. Double-digit Growth Rate of the Pharmaceuticals Industry in Asia Pacific Boosts the API Market, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014  As physicians seek information about drugs ... to learn about new therapies or ask questions ... new report by global sales and marketing consultants ... via a customized mix of digital media and ... to engage with physicians. And, productive engagement with ...
(Date:9/22/2014)... BARCELONA , España, September 23, 2014 ... nube permite que los patrocinadores de ensayos clínicos satisfagan ... a la accesibilidad y exhaustividad de los expedientes permanentes ... La mayor encuesta sobre TMF en el ... un aumento en el número de patrocinadores de ensayos ...
(Date:9/22/2014)... Calif. , Sept. 22, 2014 Avanir ... that it is offering to sell $200 million of ... Morgan, Deutsche Bank Securities and BofA Merrill Lynch are ... to grant the underwriters a 30-day option to purchase ... shares to be sold in the offering are being ...
Breaking Medicine Technology:As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 2El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 3El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 4El acceso remoto al eTMF se duplicará en 2015, revela una encuesta general del sector 5Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 2Avanir Pharmaceuticals Announces Proposed Public Offering of Common Stock 3
... N.J., Oct. 31, 2011 Johnson & Johnson Pharmaceutical ... has submitted a supplemental New Drug Application (sNDA) to ... ® ER (tapentadol) extended-release tablets, an oral analgesic, ... peripheral neuropathy (DPN) in adults. The FDA approved NUCYNTA ...
... NEW YORK, Oct. 31, 2011 Reportlinker.com ... is available in its catalogue: ... 2016 http://www.reportlinker.com/p0254518/Germany-Surgical-Equipment-Market-Outlook-to-2016.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Surgical_Equipment ... to 2016 Summary ...
Cached Medicine Technology:Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 2Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 3Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 4Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 5Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 6Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 7Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 8Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 9Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 10Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 11Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 12Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 13Germany Surgical Equipment Market Outlook to 2016 2Germany Surgical Equipment Market Outlook to 2016 3Germany Surgical Equipment Market Outlook to 2016 4Germany Surgical Equipment Market Outlook to 2016 5Germany Surgical Equipment Market Outlook to 2016 6Germany Surgical Equipment Market Outlook to 2016 7Germany Surgical Equipment Market Outlook to 2016 8Germany Surgical Equipment Market Outlook to 2016 9
(Date:9/23/2014)... 23, 2014 On September 23, 2014, My ... for an episode. Simmons is the founder of Traveler of ... audience would like to know. At the start of the ... to start this magazine?” Simmons replied by saying, “I had ... In 2005, I quit that and decided to start my ...
(Date:9/23/2014)... The U.S. Pharmacopeial Convention (USP) has submitted ... (WHO) regarding the assignment of Biological Qualifiers (BQ) to ... Expert Group of the Programme of International Nonproprietary Names ... naming of all biologicals that is consistent with existing, ... these drugs. , Hence, USP supports the concept ...
(Date:9/23/2014)... Healthcare Solutions, the parent ... and Modern Medical, today announced the expansion ... with EMPLOYERS®, America's small business insurance specialist®. ... has saved millions of dollars in workers’ ... Since May 2013, Healthcare Solutions has worked ...
(Date:9/23/2014)... 2014 (HealthDay News) -- Fear of losing your job can ... European study. The study involved more than 7,000 employed ... downturn in Europe, the workers answered questions about the respiratory ... their job within two years. More than 100 new ... of whom were women, during the study period. The ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 Altec ... and workflow solutions, will be a participating sponsor ... annual Microsoft Dynamics® GP customer conference, from 8:00am ... Meydenbauer Center in Bellevue, Washington. The Resource Group ... overcome challenges during growth and connect disparate ...
Breaking Medicine News(10 mins):Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2Health News:USP Comments to WHO Regarding Biologics Qualifier Proposal 2Health News:EMPLOYERS® Expands Pharmacy Services with Healthcare Solutions After Effective Pilot Program 2Health News:EMPLOYERS® Expands Pharmacy Services with Healthcare Solutions After Effective Pilot Program 3Health News:Job Worries Can Raise Asthma Risk, Study Says 2Health News:Altec to Sponsor The Resource Group’s Annual RG Connect Conference 2Health News:Altec to Sponsor The Resource Group’s Annual RG Connect Conference 3
... can be severe , , MONDAY, May 18 (HealthDay News) -- ... as it tries to serve the poor, researchers from North ... recovering from breast cancer do not take the drugs ... do not follow instructions to take these drugs, medications that ...
... CLC 27th Annual Conference on Professional Issues May 24 in ... Council, the leading nonprofit professional association serving child life specialists, ... recipient of the 2009 Distinguished Service Award, in recognition of ... Utica College was selected by ...
... retail locationNORTH BERGEN, N.J., May 18 Eco Shoppe has announced ... Eco Shoppe store in the country. Eco Shoppe is a ... products directly to consumers through exciting new stores as well as ... will open in Austin on May 21 and is owned and ...
... made on May 13, 2009, as Minnesota became the ... health provider into state statute - enabling students who ... model to become licensed to practice. The Minnesota ... a bill establishing the Dental Therapist and Advanced Dental ...
... Study Confirms Previous Positive Findings on Efficacy and ... Deutsche Bank 34th Annual Healthcare Conference Today at ... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... from its Phase IIb clinical trial known as ...
... study finds , , MONDAY, May 18 (HealthDay News) -- People ... chance of living a longer and healthier life. , Researchers ... data from 2002 to 2007, found that that wealthier people ... were less likely to have depression, high-blood pressure or diabetes ...
Cached Medicine News:Health News:Poor Women Seem to Be Skipping Breast Cancer Drugs 2Health News:Utica College to Receive Child Life Council Spirit of Giving Award 2Health News:Utica College to Receive Child Life Council Spirit of Giving Award 3Health News:First Eco Shoppe Opening in Austin on May 21 2Health News:First Eco Shoppe Opening in Austin on May 21 3Health News:First Eco Shoppe Opening in Austin on May 21 4Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 2Health News:Minnesota Passes Legislation Allowing Mid-level Oral Health Provider 3Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 2Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 3Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 4Health News:Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain 5Health News:Money May Matter, Health-Wise, in Old Age 2
... GE Healthcare is ... in best-in-class analysis programs ... area monitoring device. With ... 12SL, Gender-Specific, and ACI-TIPI, ...
... The Affinity pacemaker family ... smallest, truly automatic devices. ... combination of advanced technologies ... DR pacemaker incorporates the ...
... small bench top chemistry analyzer that utilizes dry ... with results available within 8 - 15 minutes. ... instrument accepts whole blood samples and is calibrated ... At the conclusion of testing, results are available ...
... is a battery-backed up, microprocessor based, quality instrument ... It stores and displays a chart on its ... scrolled through or zoomed into and out of, ... to 3 months can be seen at one ...
Medicine Products: